WooEB Press Release Distribution Service for Social Networking

The thyroid cancer market was estimated at $55m in 2010

London 4/11/2011 07:00 AM GMT (WooEB)

We estimated that the thyroid cancer market was worth $55m in 2010. The major reason for the limited market revenues was the lack of approved drugs for the treatment of thyroid cancer. Thyroid cancer is mainly treated by surgery and radiotherapy. Chemotherapy has fewer roles to play in the treatment. Mainly doxorubicin is used as an off-label drug for treating the patients with anaplastic thyroid cancer; also some other off-label drugs such as cisplatin and carboplatin are used, but they have lower response rates.

The high growth forecast for the thyroid cancer therapeutics market is primarily attributed to a strong pipeline. The upcoming four pipeline molecules (Pre-registration (1) and Phase III (3)) in the next seven years will take a steep rise in the market. Overall, between 2010 and 2017, the thyroid cancer market is expected to grow at a CAGR (Compound Annual Growth Rate) of 27.34% to reach $298m by 2017.

Strong Pipeline Candidates are Expected to Intensify Future Competition

We found that the pipeline of the thyroid cancer market is strong, as there are 27 molecules in different stages of development. There are four promising molecules in Pre-registration (1) and Phase III (3). These drugs are expected to get approved in the next seven years. Zactima, Zybrestat and XL184 have been granted orphan drug status by the FDA.

These new molecules with novel mechanisms of action will meet the current unmet needs and will give physicians a better choice for the treatment of thyroid cancer. Once these molecules get approved it will intensify competition in the market. In summary, the global thyroid cancer therapeutics market is heading towards a strong competitive landscape.

The Current Competition in the Thyroid Cancer Market is Weak

We found that the current competition in the thyroid cancer market is weak, as the market is devoid of any approved drug treatment. Surgery is the most effective mode of treatment. Some chemotherapy drugs are used off-label, such as doxorubicin which is aimed at managing conditions that contribute to thyroid cancer. Hence, there is an open space for a company to enter into this market and take substantial market share.

High Unmet Needs Exist in the Thyroid Cancer Market

The thyroid cancer market poses high unmet needs due to the lack of approved drugs for treating thyroid cancer. It is mainly treated by surgery; doxorubicin, cisplatin and carboplatin have an off-label use. To satisfy the high unmet need in the existing market, a product needs to overcome the prevailing product weaknesses and adverse effects of the off-label products presently used in the treatment of thyroid cancer. The promising drugs in the pipeline will increase the scope for the thyroid cancer market.

Report Summary

This report is an essential source of information and analysis on the global Thyroid Cancer Therapeutics market. The report identifies the key trends shaping and driving the global Thyroid Cancer Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Thyroid Cancer Therapeutics sector.

Report Scope

The report provides information on the key drivers and challenges of the Thyroid Cancer Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Thyroid Cancer Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Thyroid Cancer Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Thyroid Cancer Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Thyroid Cancer Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Thyroid Cancer Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Thyroid Cancer Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global Thyroid Cancer Therapeutics market landscape? - Identify, understand and capitalize.

Click for report details: Thyroid Cancer Therapeutics - Pipeline Assessment and Market Forecasts to 2017



News Alerts

Receive alerts for Companiesandmarkets.com to your inbox. Sign up for News Alerts